Guidelines for the management of arterial hypertension

[1]  G. Barton,et al.  Randomised controlled trial , 2016 .

[2]  Mark N. Puttick,et al.  Size is not everything: rates of genome size evolution, not C-value, correlate with speciation in angiosperms , 2015, Proceedings of the Royal Society B: Biological Sciences.

[3]  L. Nieman,et al.  Cushing's syndrome , 2015, The Lancet.

[4]  Jan A Staessen,et al.  White-coat hypertension: new insights from recent studies. , 2013, Hypertension.

[5]  淳一 佐々木.  Air Force/Texas Coronary Atherosclerosis Prevention Study , 2008 .

[6]  T. Ohkubo,et al.  [The Ohasama study]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[7]  C. Mogensen,et al.  Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes * , 2003, Journal of internal medicine.

[8]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[9]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[10]  S. Tonstad,et al.  Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. , 2003, European heart journal.

[11]  Peter Sleight,et al.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. , 2003, JAMA.

[12]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[13]  Bryan Williams,et al.  Treating hypertension: it is not how you start but where you end that matters. , 2003, Journal of hypertension.

[14]  N. Kaplan.  The meaning of ALLHAT , 2003, Journal of hypertension.

[15]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[16]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[17]  P. Ridker.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[18]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[19]  C. Ballantyne.  Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA) , 2003 .

[20]  G. Mancia,et al.  New year, new challenges. , 2003, Journal of hypertension.

[21]  Deeb N Salem,et al.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. , 2003, Journal of the American College of Cardiology.

[22]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[23]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[24]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[25]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[26]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[27]  Majid Ezzati,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[28]  A. Zanchetti,et al.  Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study , 2002, Journal of hypertension.

[29]  N. Wong,et al.  Cardiovascular risk evaluation: an inexact science , 2002, Journal of hypertension.

[30]  Hans L Hillege,et al.  Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.

[31]  M. Nieminen,et al.  Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. , 2002, JAMA.

[32]  L. Nieman.  Diagnostic Tests for Cushing's Syndrome , 2002, Annals of the New York Academy of Sciences.

[33]  M. Nieminen,et al.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , 2002, Journal of hypertension.

[34]  S. Taddei,et al.  Endothelial dysfunction in essential hypertension: clinical implications. , 2002, Journal of hypertension.

[35]  G. Mancia,et al.  Systolic and diastolic blood pressure control in antihypertensive drug trials. , 2002, Journal of hypertension.

[36]  G. Reaven.  Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular Disease , 2002, Circulation.

[37]  M. Nieminen,et al.  Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study , 2002, Journal of hypertension.

[38]  G. Mancia,et al.  Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey , 2002, Journal of hypertension.

[39]  C. Tsalamandris,et al.  Albumin to creatinine ratio: a screening test with limitations. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  D. Altman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[41]  C. Reid,et al.  `Reverse white-coat hypertension’ in older hypertensives , 2002, Journal of hypertension.

[42]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[43]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[44]  J. Blacher,et al.  Central Pulse Pressure and Mortality in End-Stage Renal Disease , 2002, Hypertension.

[45]  A. Simon,et al.  Intima–media thickness: a new tool for diagnosis and treatment of cardiovascular risk , 2002, Journal of hypertension.

[46]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[47]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[48]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[49]  J F Potter,et al.  Twenty-four hour systolic blood pressure predicts long-term mortality following acute stroke , 2001, Journal of hypertension.

[50]  F. Magrini,et al.  High prevalence of cardiac and extracardiac target organ damage in refractory hypertension , 2001, Journal of hypertension.

[51]  A. Zanchetti,et al.  Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study , 2001, Journal of hypertension.

[52]  G Parati,et al.  Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA) , 2001, Journal of hypertension.

[53]  S. Yusuf,et al.  Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril , 2001, Circulation.

[54]  M. O'Rourke,et al.  Prospective Evaluation of a Method for Estimating Ascending Aortic Pressure From the Radial Artery Pressure Waveform , 2001, Hypertension.

[55]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[56]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[57]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[58]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[59]  S. Kjeldsen,et al.  Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men , 2001, Journal of hypertension.

[60]  T. Mengden,et al.  Tele-monitoring of home blood pressure. , 2001, Blood pressure monitoring.

[61]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[62]  François Gueyffier,et al.  A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials , 2001, BMJ : British Medical Journal.

[63]  A. Simon,et al.  Differential Effects of Nifedipine and Co-Amilozide on the Progression of Early Carotid Wall Changes , 2001, Circulation.

[64]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[65]  C. Held,et al.  Regression of left ventricular hypertrophy in human hypertension with irbesartan , 2001, Journal of hypertension.

[66]  R. Fagard.  Exercise characteristics and the blood pressure response to dynamic physical training. , 2001, Medicine and science in sports and exercise.

[67]  A. Zanchetti,et al.  Impact of the Gubbio population study on community control of blood pressure and hypertension , 2001, Journal of hypertension.

[68]  G. Parati,et al.  [Blood pressure variability]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[69]  P. Ducimetiere,et al.  Aortic Stiffness Is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients , 2001, Hypertension.

[70]  J. Ménard,et al.  Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study , 2001, Journal of hypertension.

[71]  J. Gardin,et al.  Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. , 2001, Journal of the American College of Cardiology.

[72]  Martin G. Larson,et al.  Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging?: The Framingham Heart Study , 2001, Circulation.

[73]  G Parati,et al.  Blood pressure measuring devices: recommendations of the European Society of Hypertension , 2001, BMJ : British Medical Journal.

[74]  P. Ghahramani,et al.  Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials , 2001, Heart.

[75]  S. Yusuf,et al.  Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) , 2001, Circulation.

[76]  S J Riederer,et al.  High-spatial-resolution contrast-enhanced MR angiography of the renal arteries: a prospective comparison with digital subtraction angiography. , 2001, Radiology.

[77]  A. Zanchetti,et al.  Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. , 2001, Journal of the American Society of Nephrology : JASN.

[78]  G. Dekker,et al.  Primary, secondary, and tertiary prevention of pre-eclampsia , 2001, The Lancet.

[79]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .

[80]  T. Hedner,et al.  Stroke is More Common than Myocardial Infarction in Hypertension: Analysis based on 11 Major Randomized Intervention Trials , 2001, Blood pressure.

[81]  H. Crijns,et al.  Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial , 1999, Journal of hypertension.

[82]  R. Gordon.  Diagnostic investigations in primary aldosteronism , 2001 .

[83]  Anna Buehring,et al.  From theory into practice , 2001 .

[84]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[85]  P. Choyke,et al.  Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. , 2000, The Journal of clinical endocrinology and metabolism.

[86]  G Parati,et al.  Ambulatory Blood Pressure Monitoring and Organ Damage , 2000, Hypertension.

[87]  A. Rocchini.  Obesity hypertension, salt sensitivity and insulin resistance. , 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[88]  Michael E. Miller,et al.  Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events , 2000, Circulation.

[89]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[90]  John S. Scott,et al.  Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. , 2000, Journal of the American College of Cardiology.

[91]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[92]  Michael C. Fiore,et al.  A Clinical Practice Guideline for Treating Tobacco Use and Dependence A US Public Health Service Report , 2000 .

[93]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[94]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[95]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[96]  M. Schroll,et al.  Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. , 2000, Hypertension.

[97]  Karla Kerlikowske,et al.  Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials , 2000, The Lancet.

[98]  S. F. Olsen,et al.  Randomised clinical trials of fish oil supplementation in high risk pregnancies , 2000, BJOG : an international journal of obstetrics and gynaecology.

[99]  E. Vartiainen,et al.  Cardiovascular risk factor changes in Finland, 1972-1997. , 2000, International journal of epidemiology.

[100]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[101]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[102]  M. Swiet.  Maternal blood pressure and birthweight , 2000, The Lancet.

[103]  G Koren,et al.  Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis , 2000, The Lancet.

[104]  F. Luft,et al.  Molecular genetics of human hypertension. , 1998, Current opinion in nephrology and hypertension.

[105]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[106]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[107]  W. Cushman,et al.  The role of diastolic blood pressure when treating isolated systolic hypertension. , 1999, Archives of internal medicine.

[108]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[109]  Gianfranco Parati,et al.  Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. , 1999 .

[110]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[111]  V. Burke,et al.  Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. , 1999, Journal of hypertension.

[112]  D. Levy,et al.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. , 1999, Circulation.

[113]  R. Pini,et al.  Cardiac and Arterial Target Organ Damage in Adults with Elevated Ambulatory and Normal Office Blood Pressure , 1999, Annals of Internal Medicine.

[114]  G. Eknoyan,et al.  Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[115]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[116]  C. Bulpitt,et al.  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[117]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[118]  Z. Pausova,et al.  Gene-environment interactions in hypertension , 1999, Current hypertension reports.

[119]  R. Kronmal,et al.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.

[120]  J A Staessen,et al.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension , 1998, Journal of hypertension.

[121]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[122]  A. Zanchetti,et al.  The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long‐term randomized treatment with either verapamil or chlorthalidone on carotid intima‐media thickness , 1998, Journal of hypertension.

[123]  T. Mori,et al.  Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. , 1998, Hypertension.

[124]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[125]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[126]  R. Bigazzi,et al.  Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension , 1998, Journal of hypertension.

[127]  A. Döring,et al.  Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. , 1998, European heart journal.

[128]  K Nagai,et al.  Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasama Study. , 1998, Hypertension.

[129]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[130]  Shigeru Hisamichi,et al.  Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population‐based observation in Ohasama, Japan , 1998, Journal of hypertension.

[131]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[132]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[133]  C. Furberg,et al.  HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. , 1998, Atherosclerosis.

[134]  G. Parati,et al.  Difference between clinic and daytime blood pressure is not a measure of the white coat effect. , 1998, Hypertension.

[135]  P. Whelton,et al.  Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. , 1998, JAMA.

[136]  Beverley Balkau,et al.  High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study , 1998, Diabetes Care.

[137]  R. Schmieder,et al.  Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[138]  L. Hansson,et al.  Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. , 1998, Hypertension.

[139]  R H Selzer,et al.  The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events , 1998, Annals of Internal Medicine.

[140]  Thierry C. Gillebert,et al.  How to diagnose diastolic heart failure , 1998 .

[141]  P. Thürmann,et al.  Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. , 1998, Circulation.

[142]  A. Amos,et al.  The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010 , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[143]  L Guize,et al.  Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. , 1997, Hypertension.

[144]  B. Magnani,et al.  Clinical results of the Verapamil in Hypertension and Atherosclerosis Study , 1997 .

[145]  T. Ohkubo,et al.  Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. , 1997, American journal of hypertension.

[146]  M. Woodward,et al.  Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study , 1997, BMJ.

[147]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[148]  Arno W. Hoes,et al.  Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.

[149]  Y. Imai,et al.  Reproducibility of home blood pressure measurements over a 1-year period. , 1997, American journal of hypertension.

[150]  R. Kronmal,et al.  Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. , 1997, Stroke.

[151]  R. Doughty,et al.  Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. , 1997, European heart journal.

[152]  Giuseppe Mancia,et al.  Ambulatory Blood Pressure Is Superior to Clinic Blood Pressure in Predicting Treatment-Induced Regression of Left Ventricular Hypertrophy , 1997 .

[153]  S. Haffner.  The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities. , 1997, Journal of diabetes and its complications.

[154]  J. Moodley,et al.  Drug management of hypertensive disorders of pregnancy. , 1997, Pharmacology & therapeutics.

[155]  R H Fagard,et al.  Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. , 1997, Hypertension.

[156]  H. Drexler,et al.  Endothelial dysfunction: clinical implications. , 1997, Progress in cardiovascular diseases.

[157]  K. Zarnke,et al.  A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. , 1997, American journal of hypertension.

[158]  J F Toole,et al.  Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. , 1996, Stroke.

[159]  M. Laakso,et al.  Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. , 1996, Stroke.

[160]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[161]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[162]  P. Schollmeyer,et al.  Diagnosis of renovascular disease by intra- and extrarenal Doppler scanning. , 1996, Kidney international.

[163]  M. Rocco,et al.  Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. , 1996, JAMA.

[164]  E. Grossman,et al.  Diabetic and Hypertensive Heart Disease , 1996, Annals of Internal Medicine.

[165]  J. Staessen,et al.  Prognostic value of invasive hemodynamic measurements at rest and during exercise in hypertensive men. , 1996, Hypertension.

[166]  S. Fo.  Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. , 1996 .

[167]  T. Ohkubo,et al.  Predictive power of screening blood pressure, ambulatory blood pressure and blood pressure measured at home for overall and cardiovascular mortality: a prospective observation in a cohort from Ohasama, northern Japan. , 1996, Blood pressure monitoring.

[168]  B. Lernfelt,et al.  15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.

[169]  P. Hamet,et al.  Shanghai trial of nifedipine in the elderly (STONE). , 1996, Journal of hypertension.

[170]  S. Kjeldsen,et al.  Exercise blood pressure predicts mortality from myocardial infarction. , 1996, Hypertension.

[171]  P Omvik,et al.  How smoking affects blood pressure. , 1996, Blood pressure.

[172]  G. Reaven,et al.  Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. , 1996, The New England journal of medicine.

[173]  J. Laragh,et al.  Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. , 1996, Circulation.

[174]  D. Kromhout.  Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[175]  G. Mancia,et al.  Ambulatory blood pressure normality: results from the PAMELA study , 1995, Journal of hypertension.

[176]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[177]  A D Oxman,et al.  No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[178]  J. Cutler,et al.  Blood Pressure and Mortality Among Men With Prior Myocardial Infarction , 1995 .

[179]  D. Rizzoni,et al.  Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment , 1995, Journal of hypertension.

[180]  I. Hjermann,et al.  Effect of dietary counselling on blood pressure and arterial plasma catecholamines in primary hypertension. , 1995, American journal of hypertension.

[181]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[182]  G. Colditz,et al.  Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women , 1995, Annals of Internal Medicine.

[183]  G. Parati,et al.  Lack of placebo effect on ambulatory blood pressure. , 1995, American journal of hypertension.

[184]  J. Laragh,et al.  Diagnosis and Treatment of Primary Hyperaldosteronism , 1994, Annals of Internal Medicine.

[185]  H. Parving,et al.  Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V , 1994, Diabetes Care.

[186]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice , 1994 .

[187]  D. Levy,et al.  Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. , 1994, Circulation.

[188]  S. Yusuf,et al.  Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. , 1994, Circulation.

[189]  E. Bravo,et al.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. , 1994, Endocrine reviews.

[190]  M. Stowasser,et al.  HIGH INCIDENCE OF PRIMARY ALDOSTERONISM IN 199 PATIENTS REFERRED WITH HYPERTENSION , 1994, Clinical and experimental pharmacology & physiology.

[191]  C. Reid,et al.  Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects , 1994, Journal of hypertension.

[192]  D. Mant,et al.  Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation , 1994, The Lancet.

[193]  J. Dillon.  The quantitative relationship between treated blood pressure and progression of diabetic renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[194]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[195]  G Mancia,et al.  Prognostic value of 24-hour blood pressure variability , 1993, Journal of hypertension.

[196]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[197]  Giuseppe Mancia,et al.  1993 Guidelines for the Management of Mild Hypertension: Memorandum From a World Health Organization/ International Society of Hypertension Meeting , 1993 .

[198]  W. G. Walker.  Hypertension-related renal injury: a major contributor to end-stage renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[199]  Clyne,et al.  Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. , 1993, Journal of hypertension.

[200]  J. Salonen,et al.  Ultrasound B-mode imaging in observational studies of atherosclerotic progression. , 1993, Circulation.

[201]  K. Arakawa.  Antihypertensive mechanism of exercise. , 1993, Journal of hypertension.

[202]  J. Staessen,et al.  A meta-analysis of outcome trials in elderly hypertensives. , 1992, Journal of hypertension.

[203]  R. Vandongen,et al.  Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. , 1992, Hypertension.

[204]  M. Schroll,et al.  The Glostrup Population Studies, 1964-1992. , 1992, Danish medical bulletin.

[205]  J. Sowers,et al.  Diabetes mellitus and hypertension. , 1992, Hypertension.

[206]  H. Köhler,et al.  Acanthocyturia--a characteristic marker for glomerular bleeding. , 1991, Kidney international.

[207]  J. Staessen,et al.  Mean and range of the ambulatory pressure in normotensive subjects from a meta-analysis of 23 studies. , 1991, The American journal of cardiology.

[208]  J. Laragh,et al.  Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.

[209]  P. Allhoff,et al.  The Framingham Offspring Study , 1991 .

[210]  A. Quyyumi,et al.  Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. , 1990, The New England journal of medicine.

[211]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[212]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[213]  G. Schillaci,et al.  Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. , 1990, Circulation.

[214]  S. Sans,et al.  Recruitment methods and differences in early, late and non-respondents in the first MONICA-Catalonia population survey. , 1990, Revue d'epidemiologie et de sante publique.

[215]  D. Simonson.  Etiology and Prevalence of Hypertension in Diabetic Patients , 1988, Diabetes Care.

[216]  P. Wilson,et al.  Incidence of Diabetic Retinopathy and Relationship to Baseline Plasma Glucose and Blood Pressure , 1988, Diabetes Care.

[217]  R. Vandongen,et al.  REGULAR ALCOHOL USE RAISES BLOOD PRESSURE IN TREATED HYPERTENSIVE SUBJECTS A Randomised Controlled Trial , 1987, The Lancet.

[218]  G Parati,et al.  Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. , 1987, Journal of hypertension.

[219]  R. Vandongen,et al.  Vegetarian diet in mild hypertension: a randomised controlled trial. , 1986, British medical journal.

[220]  J. Neaton,et al.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.

[221]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[222]  S. M. Collins,et al.  Ultrasonic backscatter and collagen in normal ventricular myocardium. , 1984, Circulation.

[223]  M. Blaufox,et al.  The effect of treatment on mortality in "mild" hypertension: results of the hypertension detection and follow-up program. , 1982, The New England journal of medicine.

[224]  N. Reichek,et al.  Left Ventricular Hypertrophy: Relationship of Anatomic, Echocardiographic and Electrocardiographic Findings , 1981, Circulation.

[225]  F. Messerli,et al.  Serum uric acid in essential hypertension: an indicator of renal vascular involvement. , 1980, Annals of internal medicine.

[226]  M. New,et al.  A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. , 1979, The Journal of clinical endocrinology and metabolism.

[227]  N. M. Keith,et al.  Some Different Types Of Essential Hypertension: Their Course And Prognosis , 1939, The American journal of the medical sciences.

[228]  T. Kollevold,et al.  [Primary aldosteronism]. , 1969, Nordisk medicin.

[229]  G. Perera.  Hypertensive vascular disease; description and natural history. , 1955, Journal of chronic diseases.